| Authors: |
Miller WG; Department of Pathology, Virginia Commonwealth University, Richmond, VA; greg.miller@vcuhealth.org., Horowitz GL; Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA;, Ceriotti F; Former Chair of the IFCC Committee on Reference Intervals and Decision Limits (2006-2010) and collaborator in the CLSI document EP 28-A3, and Clinical Laboratory Service, San Raffaele Hospital, Milano, Italy;, Fleming JK; Vice President and Director, Department of Science and Technology, Laboratory Corporation of America, Holdings, Elon, NC;, Greenberg N; Principal Consultant, Neil Greenberg Consulting, LLC, Rochester, NY, and Convenor, ISO/TC212 Working Group 2;, Katayev A; Associate Vice President and Director, Clinical Science Assessment, Department of Science and Technology, Laboratory Corporation of America Holdings, Elon, NC;, Jones GR; Chemical Pathologist, SydPath, Department of Chemical Pathology, St. Vincent's Hospital, Sydney, and Associate Professor, Faculty of Medicine, University of New South Wales, Sydney, Australia;, Rosner W; Professor of Medicine, Department of Medicine, Columbia University, College of Physicians and Surgeons, New York, NY;, Young IS; Professor of Medicine, Department of Medicine, Queen's University, Belfast, Wellcome Research Laboratories Mulhouse Building, Royal Victoria Hospital, Belfast, UK. |
